LONG COURSE Wednesday, March 5, 2007   —  8:00 AM - 5:30 PM Convention Center Korbel Ballroom 4 TUMORS OF THE KIDNEYS AND URINARY BLADDER Click the button above to add this event to your Itinerary Planner... COURSE DIRECTORS: John N. Eble, MD Indiana University School of Medicine Indianapolis, IN David J. Grignon, MD Indiana University School of Medicine Indianapolis, IN The aim of this course is to provide the practicing pathologist and pathologist in training with a comprehensive update on the pathology of tumors of the kidneys and urinary bladder through a series of lectures given by experts on these subjects. The first half of the course will deal with the pathology of common and uncommon neoplasms of the epithelium of the renal tubules, pathology of mesenchymal and mixed renal neoplasms and with the staging ad grading of renal cell carcinoma. The second half will turn to the urinary bladder and will cover tumor-like conditions, the diagnosis of urothelial carcinoma from urine, and other important aspects of urothelial carcinoma including classification, staging and reporting, and common and uncommon variants. AGENDA 8:00 Welcome and Introduction John N. Eble, M.D. 8:05 Pathology of the common renal cell neoplasms: clear cell renal cell carcinoma, papillary renal cell carcinoma, chromophobe renal cell carcinoma, and renal oncocytoma Victor E. Reuter, M.D., Memorial Sloan-Kettering Cancer Center, New York, NY To discuss the morphologic spectrum, immunophenotype and differentiial diagnosis of the most common renal epithelial tumors. To define the clinical and molecular characteristics of each of these entities. 8:45 Pathology of selected uncommon and recently described renal cell neoplasms John R. Srigley, M.D., FRCPC, Credit Valley Hospital, Mississauga, ON, Canada To describe the spectrum of collecting duct neoplasia including renal medullary carcinoma. To present the clinical and pathological features of recently described renal epithelial tumors including mucinous tubular and spindle cell carcinoma, tubulocystic carcinoma, translocation carcinoma and post-neuroblastoma carcinoma. To illustrate where appropriate the diagnostic role of special studies including immunohistochemistry and molecular pathology. 9:15 Question Period 9:20 Break (Exhibits, Poster Session V, Coffee in Exhibit Hall A) 10:45 Grading and staging of renal cell carcinomas Brett Delahunt, M.D., FRCPA, Wellington School of Medicine, Wellington, New Zeland To review the evolution of the classifications for grading and staging of renal cell carcinomas. To discuss current controversies in the grading and staging of renal cell carcinoma. To detail recent developments in the grading and staging of renal cell carcinoma. To outline recommendations regarding the grading and staging of renal cell carcinoma based upon current evidence. 11:15 Pathology of mesenchymal and mixed renal neoplasms John N. Eble, M.D., Indiana University School of Medicine, Indianapolis, IN To provide a detailed review of the pathologic and clinical features of angiomyolipoma and its variants, along with differential diagnostic considerations. To provide a detailed review of the of the pathologic features of the renal neoplasms composed of mixtures of epithelial and stromal elements. To discuss the current controversy concerning cystic nephroma and mixed epithelial and stromal tumor of kidney. 11:40 Question Period 11:45 LUNCH 1:00 Introduction to Bladder Section David J. Grignon, M.D., Indiana University School of Medicine, Indianapolis, IN 1:05 Tumor-like conditions of the urinary bladder Robert H. Young, M.D., Massachusetts General Hospital and Harvard Medical School, Boston, MA To provide an overview of the spectrum of lesions that grossly, microscopically, or from both perspectives may be misinterpreted as bladder cancer. To emphasize the importance of the clinical background in prompting the correct diagnosis in a number of these instances. To describe in detail the gross and microscopic features of the most important entities with emphasis on newer information. 1:35 Diagnosis of urothelial carcinoma from urine Bernard Têtu, M.D., FRCPC, L’Hotel Dieu de Quebec, Quebec, PQ, Canada To provide an overview of currently available noninvasive urine tests that have been developed to improve the sensitivity of urine cytology. To compare the advantages and limitations of most common tests. To discuss how such tests may influence the urologist to modify the frequency of diagnostic and follow-up cystoscopy. To understand how such tests may help cytologists and pathologists to be more specific in cases of atypia suspicious for malignancy. 2:05 The WHO classification of urothelial neoplasia David J. Grignon, M.D., Indiana University School of Medicine, Indianapolis, IN To understand the history and ideas that led to the development of the current WHO classification of urothelial neoplasia. To be able to apply histological criteria in correctly classifiying both papillary and flat neoplastic processes of the urothelium. To understand the clinical significance of the different categories. 2:40 Question Period 2:50 Break (Exhibits, Poster Session VI, Coffee in Exhibit Hall A) 4:15 Staging and reporting urothelial carcinoma of the urinary bladder Liang Cheng, M.D., Indiana University School of Medicine, Indianapolis, IN To provide an overview of current TNM staging system. To discuss morphologic criteria and pitfalls in the diagnosis of invasion in the biopsy specimen. To understand the current challenges in the substaging of pT1-4 bladder cancer. To describe parameters in the reporting of bladder specimens. 4:45 Variants of urothelial carcinoma Mahul B. Amin, M.D., Cedars-Sinai Health System, Los Angeles, CA To describe the spectrum of unusual histologic patterns of urothelial carcinoma. To present the diagnostic and differential diagnostic dilemmas posed by urothelial carcinoma. To discuss the prognostic and therapeutic significance of reporting variants of urothelial carcinoma. 5:15 Question Period and Closing Remarks